> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Gene Therapies Panel Reviews 2 bluebird BLAs
- URL: https://www.fdaweb.com/gene-therapies-panel-reviews-2-bluebird-blas/
- Published: 2022-04-13T12:00:00.000Z
- Updated: 2026-09-14T17:40:35.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5151583

*Federal Register* notice: FDA has announced a 6/9-10 Cellular, Tissue and Gene Therapies Advisory Committee meeting. Panel members are scheduled to discuss two bluebird bio BLAs: (**1**) a BLA for elivaldogene autotemcel for treating patients younger than 18 years of age with early cerebral adrenoleukodystrophy who do not have an available and willing human leukocyte antigen-matched sibling hematopoietic stem cell donor; and (**2**) a BLA for betibeglogene autotemcel for treating patients with β-thalassemia who require regular red blood cell transfusions. To view the notice, click [here](https://public-inspection.federalregister.gov/2022-08022.pdf?ref=fdaweb.com).